Endometriosis is a chronic gynecologic condition characterized by growth of endometrial tissue outside the uterus.^[@R1]^ Pain symptoms are a central feature of endometriosis, along with infertility and chronic fatigue,^[@R1],[@R2]^ and current treatment guidelines prioritize pain management.^[@R3],[@R4]^ Endometriosis reduces women's health-related quality of life (HRQOL),^[@R5]^ resulting in impairments in physical functioning,^[@R6]--[@R9]^ diminished social life, difficulties in intimate relationships,^[@R6],[@R7],[@R10],[@R11]^ and decreased productivity.^[@R6]--[@R8],[@R12]^

Patient-reported outcome measures such as the EHP-30 (Endometriosis Health Profile-30)^[@R13]--[@R15]^ are increasingly employed to evaluate therapeutic efficacy and guide clinical decision making.^[@R16]^ In 2009, the U.S. Food and Drug Administration published guidance on using patient-reported outcome measures in clinical trials, emphasizing the establishment of meaningful changes at the patient level.^[@R17]^ Individual patient-reported outcome score changes (responder definitions) over a predetermined time period that would be interpreted as treatment benefits can be used to assess treatment effects perceived as meaningful by the patient.^[@R17],[@R18]^

Few studies have defined clinically meaningful score changes for patient-reported outcomes used in endometriosis.^[@R19]--[@R22]^ Responder definitions were previously determined for EHP-30 subscales based on data from patients with moderate to severe pain associated with endometriosis in the ELARIS EM-I, and EM-II trials.^[@R23]^ In the current post hoc analysis, responder definitions for EHP-30 subscales were applied to pooled ELARIS trial data^[@R24]^ to determine whether treatment with elagolix, an oral nonpeptide gonadotropin-releasing hormone antagonist,^[@R25]^ was associated with clinically meaningful improvements in HRQOL compared with placebo.
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==========================
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METHODS {#s2}
=======

Data were pooled from two similar phase III randomized controlled trials, ELARIS EM-I (NCT01620528) and ELARIS EM-II (NCT01931670), which evaluated the efficacy and safety of elagolix for the treatment of moderate to severe pain associated with endometriosis.^[@R24]^ The study designs and eligibility criteria have been previously described.^[@R24]^ Briefly, premenopausal women aged 18--49 years who received a surgical diagnosis of endometriosis in the previous 10 years and who had moderate to severe pain associated with endometriosis were eligible for the studies. Participants were randomized 2:2:3 to receive elagolix 150 mg once daily (150-mg cohort), 200 mg twice daily (200-mg cohort), or placebo for 6 months with a 12-month follow-up period. The primary endpoints in the studies were the proportion of patients with a clinical response for dysmenorrhea and nonmenstrual pelvic pain at month 3 of treatment, where response was defined as clinically meaningful reduction in pain score, and decreased or stable use of rescue analgesics.^[@R24]^ Secondary endpoints included efficacy evaluations per patient-reported outcomes, including assessment of HRQOL.

Patients in the two trials were administered the EHP-30 questionnaire^[@R15]^ at baseline, and at months 1, 3, and 6 of treatment. The EHP-30 is a validated disease specific questionnaire with 30 questions that encompass five core scales: pain, control and powerlessness, emotional well-being, social support, and self-image.^[@R15]^ The EHP-30 modular questionnaires address additional scales that may not apply to all women with endometriosis,^[@R14],[@R15]^ including the sexual intercourse scale, which was administered to patients in these trials. The EHP-30 questions are asked regarding endometriosis in the previous 4 weeks and are answered on a 5-point Likert scale, where 0=never, 1=rarely, 2=sometimes, 3=often, and 4=always. Raw scores for the questions within a scale are summed and transformed to a 0--100 scale, with higher scores indicating worse HRQOL.^[@R14],[@R15]^

Least squares mean change from baseline to months 1, 3, and 6 was calculated for the pooled data set of patients. Differences between elagolix dose groups and placebo were derived from an analysis of covariance model, with treatment as the main effect and baseline value as a covariate. A triangulation approach was used to assess responder thresholds for the sexual relationship module and each domain of EHP-30. The triangulation methodology involved three psychometric approaches, anchor- and distribution-based analyses, and use of clinically relevant indicators (improvement in dysmenorrhea, nonmenstrual pelvic pain, and dyspareunia). The results for these three psychometric approaches as they apply to EHP-30 have been previously described.^[@R23]^ The following responder definitions for EHP-30 scales were used: pain, 30-point reduction; control and powerlessness, 35-point reduction; emotional well-being, social support, self-image, and sexual intercourse, 20-point reductions.^[@R23]^ The percentages of patients who met the responder definitions for each of the six EHP-30 scales at months 1, 3, and 6 were determined.

A binary Poisson regression analysis was performed to determine the probability of patients meeting EHP-30 responder definitions at months 3 and 6. In this model, baseline EHP-30 scores and treatment arm were independent variables, and patients given placebo were used as the reference group. Relative risk (RR) estimates, 95% CIs, and associated *P* values were generated; regression results were adjusted for differences in baseline EHP-30 domain scores. Continuous variables were summarized by means and SD and categorical variables were reported as percentages. The EHP-30 data were reported for only nonmissing responses. All data analyses were performed using SAS 9.4.

An institutional review board at each study center approved the clinical study protocol before the study was conducted. Shulman Associates IRB conducted the majority of the institutional review board approvals at each study center. The trial was conducted in accordance with the Declaration of Helsinki and International Conference on Harmonisation guidelines.^[@R24]^ Informed consent was obtained from all individuals who participated in the ELARIS EM-I and EM-II trials.^[@R24]^

RESULTS {#s3}
=======

A total of 1,686 women were randomized and treated in the ELARIS EM-I and EM-II trials, with 734 receiving placebo, 475 receiving elagolix 150 mg once daily, and 477 receiving elagolix 200 mg twice daily (Table [1](#T1){ref-type="table"}). The baseline demographics and clinical characteristics of the study populations were similar between trials and across treatment arms,^[@R24]^ allowing data from both trials to be pooled by treatment arm. Baseline pain scores for dysmenorrhea, nonmenstrual pelvic pain, and dyspareunia were highly similar between treatment arms (Table [1](#T1){ref-type="table"})^[@R23],[@R24]^

###### 

Baseline Demographics and Clinical Characteristics of the Study Population

![](ong-136-501-g001)

Women in the elagolix 200-mg cohort had significant improvements from baseline in all six EHP-30 subscale scores compared with women in the placebo group at months 1, 3 and 6 of treatment (Table [2](#T2){ref-type="table"}). In the elagolix 200-mg cohort, the greatest improvements compared with placebo (least squares mean difference±SE) were reported for pain (−21.09±1.46; 95% CI −23.95 to −18.23; *P*\<.001) and control and powerlessness (−23.10±1.78; 95% CI −26.59 to −19.61; *P*\<.001) at month 6. Improvements at month 6 were also reported for the elagolix 150-mg cohort, but the magnitude was less than in the 200-mg cohort: pain (−10.70±1.45; 95% CI −13.54 to −7.87; *P*\<.001) and control and powerlessness (−9.93±1.77; 95% CI −13.41 to −6.44; *P*\<.001).

###### 

Change From Baseline in Endometriosis Health Profile-30 Domain Scores
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At month 1, a greater percentage of women treated with either dose of elagolix achieved responses for all EHP-30 subscales except sexual intercourse, compared with those given placebo (Fig. [1](#F1){ref-type="fig"}A--F). The percentage of patients meeting responder definitions increased from month 1 to month 3 for all EHP-30 subscales, with the greatest percentage of responders consistently in the elagolix 200-mg cohort (46.4--59.9%). By comparison, 38.1--44.0% of the elagolix 150-mg cohort and 25.5--37.9% of the placebo cohort met EHP-30 responder definitions at month 3. The placebo cohort had the lowest proportion of patients meeting responder definitions in the pain subscale at month 3 (25.5%; Fig. [1](#F1){ref-type="fig"}A). For both doses of elagolix, the percentage of patients meeting responder definitions at month 3 was greatest for the control and powerlessness subscale (150 mg, 44.0%; 200 mg, 59.9%; Fig. [1](#F1){ref-type="fig"}B). Among all EHP-30 subscales, the self-image subscale had the lowest proportion of patients meeting responder definitions for both elagolix doses at month 3 (150 mg, 38.1%; 200 mg, 46.4%; Fig. [1](#F1){ref-type="fig"}E).

![Proportion of patients meeting responder definitions for EHP-30 (Endometriosis Health Profile-30) subscales at months 1, 3, and 6 of treatment. The percentages of patients who met responder definitions for the following EHP-30 subscales: pain (**A**), control and powerlessness (**B**), emotional well-being (**C**), social support (**D**), self-image (**E**), and sexual intercourse (**F**). n values indicate the total number of patients with EHP-30 scores for the indicated subscale at each timepoint per treatment arm. Responder definitions were based on the following reductions in subscale scores from baseline: pain, 30-point reduction; control and powerlessness, 35-point reduction; emotional well-being, social support, self-image, and sexual intercourse, 20-point reductions.\
Taylor. Elagolix and Meaningful EHP-30 Improvements. Obstet Gynecol 2020.](ong-136-501-g004){#F1}

From months 3--6, the percentage of patients in the placebo cohort who met responder definitions generally plateaued across subscales (Fig. [1](#F1){ref-type="fig"}A--F). In contrast, the percentage of patients in the elagolix 200-mg cohort who met responder definitions increased from month 3--6 for all subscales (52.7--66.0%). The percentages of patients in the elagolix 150-mg cohort who met responder definitions (37.2--50.1%) were relatively sustained from month 3--6 for pain, control and powerlessness, self-image, and sexual intercourse subscales. Increased proportions of patients in the elagolix 150-mg cohort were responders at month 6 for the emotional well-being (50.1%; Fig. [1](#F1){ref-type="fig"}C) and social support (43.7%; Fig. [1](#F1){ref-type="fig"}D) subscales compared with month 3 (43.3% and 39.3%, respectively).

At month 6, comparing all EHP-30 subscales, the self-image and sexual intercourse subscales had the fewest responders among the elagolix 150-mg cohort (both 37.2%; Fig. [1](#F1){ref-type="fig"}E and F). Similarly, the fewest patients in the elagolix 200-mg cohort met responder definitions at month 6 for the self-image subscale (52.7%; Fig. [1](#F1){ref-type="fig"}E).

A Poisson regression analysis with robust standard errors was performed to determine the effect of both elagolix doses compared with placebo on the probability of meeting EHP-30 responder definitions at months 3 and 6 of treatment. Unadjusted RRs and adjusted relative risks (aRRs) are provided in Tables [3](#T3){ref-type="table"} and [4](#T4){ref-type="table"}, respectively.

###### 

Unadjusted Poisson Relative Risk Estimates of Meeting Endometriosis Health Profile-30 Subscale Responder Definitions
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###### 

Adjusted Poisson Relative Risk Estimates of Meeting Endometriosis Health Profile-30 Subscale Responder Definitions
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After adjustment, the highest probability of meeting responder definitions was reported for the pain subscale at months 3 and 6 (Table [4](#T4){ref-type="table"}). At month 3, patients in the elagolix 150-mg cohort had a 66% (aRR: 1.66; 95% CI 1.40--1.97; *P*\<.001) greater probability of meeting the pain subscale responder definition than those given placebo, and patients in the elagolix 200-mg cohort had a 137% (aRR 2.37, 95% CI 2.03--2.77; *P*\<.001) greater probability than those given placebo. The probability of meeting the pain subscale responder definition at month 6 increased for both doses of elagolix; the probability for the elagolix 150-mg cohort was 75% (aRR 1.75, 95% CI 1.44--2.14; *P*\<.001) greater than placebo and 169% (aRR 2.69, 95% CI 2.26--3.21; *P*\<.001) greater than placebo for the elagolix 200-mg cohort. The probabilities of women in both elagolix dose cohorts meeting responder definitions for the control and powerlessness subscale were also significantly higher than the placebo cohort. At month 3, the probability of patients in the elagolix 150-mg cohort meeting the control and powerlessness subscale responder definition was 33% (aRR 1.33, 95% CI 1.14--1.54; *P*\<.001) greater than placebo and 84% (aRR 1.84, 95% CI 1.62--2.10; *P*\<.001) greater than placebo for patients in the elagolix 200-mg cohort. At month 6, probabilities were 50% (aRR 1.50, 95% CI 1.25--1.80; *P*\<.001) and 129% (aRR 2.29, 95% CI 1.96--2.67; *P*\<.001) greater than placebo for the elagolix 150-mg and 200-mg cohorts, respectively.

DISCUSSION {#s4}
==========

In this post hoc analysis, patients with moderate to severe pain associated with endometriosis who were treated with elagolix 150 mg once daily or 200 mg twice daily achieved clinically meaningful improvements in HRQOL in a dose-dependent manner, as observed for primary efficacy endpoints.^[@R24]^ Higher percentages of patients in the elagolix 200-mg cohort met EHP-30 responder definitions than patients in the elagolix 150-mg cohort. At month 6, significant improvements from baseline were reported for all six subscale scores in the 200-mg cohort compared with placebo, and in four subscale scores (pain, control and powerlessness, emotional well-being, and social support) in the 150-mg cohort compared with placebo. Patients treated with elagolix perceived meaningful improvements in HRQOL as early as month 1 of treatment (200-mg cohort), with sustained or further improvements through months 3 and 6. Although both doses of elagolix increased the likelihood of meeting responder definitions across HRQOL domains compared with placebo, the RR estimates were greater in the 200-mg cohort. The changes in HRQOL scores mirror the improvements observed in pain scores dysmenorrhea and nonmenstrual pelvic pain.^[@R24]^

Patients treated with elagolix had the greatest probability of meeting responder definitions for pain and control and powerlessness subscales. Elagolix results in clinically meaningful reductions in dysmenorrhea and nonmenstrual pelvic pain^[@R24]^ and significantly reduces fatigue,^[@R26]^ both of which likely contribute to clinically meaningful improvements in the control and powerlessness scale. The probability of meeting responder definitions was lowest for the sexual intercourse subscale. This finding agrees with published data showing that treatment with elagolix 200-mg twice daily resulted in significant improvement in dyspareunia scores, whereas treatment with the 150-mg once-daily dose did not.^[@R11]^

Elagolix influences more than endometriosis-associated pain, as evidenced by the proportions of patients meeting responder definitions across EHP-30 subscales. Endometriosis is associated with feelings of powerlessness and the sense that symptoms dominate one\'s life.^[@R5],[@R15],[@R27]^ Effective symptom management with elagolix may restore a sense of control and improve emotional well-being by reducing depression, anxiety, and hopelessness.^[@R5],[@R27]^ Treatment of endometriosis with elagolix may allow women to more fully engage in social activities and relationships, which often suffer owing to endometriosis symptoms.^[@R5],[@R27]^ Alleviation of dyspareunia by elagolix improves women\'s sexual quality of life,^[@R11]^ positively influencing intimate relationships that may have deteriorated.^[@R5],[@R27]^ It is common for women with endometriosis to defer or lose opportunities for career or educational advancement^[@R5],[@R7],[@R12],[@R27],[@R28]^; however, elagolix was shown to restore women\'s workplace productivity.^[@R26]^ The ability to participate in the workforce promotes mental well-being^[@R29]^ and reduces the financial burden of endometriosis.^[@R12]^ In these ways, elagolix mitigates the effects of endometriosis on women\'s HRQOL.

This study evaluated the effect of a standardized treatment regimen on clinically meaningful improvements in EHP-30 scores in women with moderate to severe endometriosis-associated pain. A PubMed search for "endometriosis EHP-30" found two other studies that evaluated clinically meaningful changes in EHP-30 scores. One study surveyed only 40 women with endometriosis who were recruited from one medical center before and after surgical intervention.^[@R22]^ The second study evaluated clinically meaningful score changes in the Dutch EHP-30 among Dutch women with endometriosis who were recruited from a medical center and patient support group who received various treatments.^[@R19]^ In contrast, our study highlights the utility of applying EHP-30 responder definitions to measure therapeutic efficacy in a large clinical trial setting.

A strength of this analysis is the large sample size derived from two phase III randomized, double-blind placebo-controlled trials. A high percentage of patients given placebo met responder definitions across EHP-30 subscales (28--38%). This placebo effect is not uncommon in a disease in which pain is the primary symptom, and the results of this analysis reflect placebo response rates observed for the trials\' primary endpoints.^[@R24]^ Despite this, regression analyses found significantly higher probabilities of meeting responder definitions for patients treated with elagolix than for those who were given placebo. The responder definitions used here were based on a patient population with moderate to severe pain associated with endometriosis and are not applicable to patients with milder endometriosis. The EHP-30 responses may be subject to recall bias; however, recall was limited to the previous 4 weeks. Additional studies are needed to access whether the effects of elagolix are sustained long-term, because the present analysis was limited to 6 months.

In summary, this analysis demonstrated that the treatment of women with moderate to severe pain associated with endometriosis with elagolix 150 mg once daily or 200 mg twice daily resulted in greater HRQOL improvements than placebo that were clinically meaningful to patients. Treatment with elagolix 200 mg twice daily was associated with a higher chance of meeting responder definitions across EHP-30 scales than elagolix 150 mg once daily. These improvements are expected to positively affect the personal and professional lives of women with endometriosis.Authors\' Data Sharing StatementWill individual participant data be available (including data dictionaries)? *Yes.*What data in particular will be shared? *Individual and trial-level data*What other documents will be available? *Protocols, clinical study reports*When will data be available (start and end dates)? *Data are made available at time of request and are accessible for 12 months, with possible extensions considered.*By what access criteria will data be shared (including with whom, for what types of analyses, and by what mechanism)? *Access to these clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). Data requests can be submitted at any time, and the data will be accessible for 12 months, with possible extensions considered. For more information on the process, or to submit a request, visit the following link:* [*https://www.abbvie.com/our-science/clinical-trials/clinical-trials-data-and-information-sharing/data-and-information-sharing-with-qualified-researchers.html*](https://www.abbvie.com/our-science/clinical-trials/clinical-trials-data-and-information-sharing/data-and-information-sharing-with-qualified-researchers.html)AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. Access is provided to anonymized, patient and trial-level data (analysis data sets), as well as other information (eg, protocols and Clinical Study Reports) from AbbVie-sponsored phase II-IV global interventional clinical trials conducted in patients (completed as of May 2004, for products and indications approved in either the United States or the European Union), as long as the trials are not part of an ongoing or planned regulatory submission). This includes requests for clinical trial data for unlicensed products and indications.*Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered. For more information on the process, or to submit a request, visit the following link:* [*https://www.abbvie.com/our-science/clinical-trials/clinical-trials-data-and-information-sharing/data-and-information-sharing-with-qualified-researchers.html*](https://www.abbvie.com/our-science/clinical-trials/clinical-trials-data-and-information-sharing/data-and-information-sharing-with-qualified-researchers.html).
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